These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19669311)

  • 21. Efficacy of tenofovir-based rescue therapy in patients with lamivudine-resistant hepatitis B virus: A systematic review and meta-analysis.
    Wang HL; Lu X; Yang X; Ning Q
    Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):447-56. PubMed ID: 26621535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Compare the effect of combined therapy between telbivudine plus adefovir dipivoxil and lamivudine plus adefovir dipivoxil corresponding to renal function in patients with hepatitis B virus infection].
    Xu J; Bao L; Wang Y; Yang L; Li WT; Zhao ZH; Li Y
    Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):288-293. PubMed ID: 29996341
    [No Abstract]   [Full Text] [Related]  

  • 23. [A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B].
    Zhao H; Zhang YX; Chen XY; Wang L; Tang XP; Si CW
    Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):294-7. PubMed ID: 17637268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapy.
    Li X; Jie Y; You X; Shi H; Zhang M; Wu Y; Lin G; Li X; Gao Z; Chong Y
    Int J Clin Exp Med; 2015; 8(11):21062-70. PubMed ID: 26885037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
    Berg T; Marcellin P; Zoulim F; Moller B; Trinh H; Chan S; Suarez E; Lavocat F; Snow-Lampart A; Frederick D; Sorbel J; Borroto-Esoda K; Oldach D; Rousseau F
    Gastroenterology; 2010 Oct; 139(4):1207-17. PubMed ID: 20600025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.
    Hou JL; Gao ZL; Xie Q; Zhang JM; Sheng JF; Cheng J; Chen CW; Mao Q; Zhao W; Ren H; Tan DM; Niu JQ; Chen SJ; Pan C; Tang H; Wang H; Mao YM; Jia JD; Ning Q; Xu M; Wu SM; Li J; Zhang XX; Ji Y; Dong J; Li J
    J Viral Hepat; 2015 Feb; 22(2):85-93. PubMed ID: 25243325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study.
    Ruggiero G; Marrone A; Rainone I; Boemio A; Adinolfi LE; Pasquale G; Rinaldi L; Guerrera B; Andreana L; Zampino R;
    Infez Med; 2016 Dec; 24(4):278-286. PubMed ID: 28011962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
    Rapti I; Dimou E; Mitsoula P; Hadziyannis SJ
    Hepatology; 2007 Feb; 45(2):307-13. PubMed ID: 17256746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.
    van Bömmel F; de Man RA; Wedemeyer H; Deterding K; Petersen J; Buggisch P; Erhardt A; Hüppe D; Stein K; Trojan J; Sarrazin C; Böcher WO; Spengler U; Wasmuth HE; Reinders JG; Möller B; Rhode P; Feucht HH; Wiedenmann B; Berg T
    Hepatology; 2010 Jan; 51(1):73-80. PubMed ID: 19998272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
    van Bömmel F; Zöllner B; Sarrazin C; Spengler U; Hüppe D; Möller B; Feucht HH; Wiedenmann B; Berg T
    Hepatology; 2006 Aug; 44(2):318-25. PubMed ID: 16871563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.
    Idilman R; Kaymakoglu S; Oguz Onder F; Ahishali E; Bektas M; Cinar K; Pinarbasi B; Karayalcin S; Badur S; Cakaloglu Y; Mithat Bozdayi A; Bozkaya H; Okten A; Yurdaydin C
    J Viral Hepat; 2009 Apr; 16(4):279-85. PubMed ID: 19222742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
    Park JG; Park SY
    Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
    Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F
    J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Tenofovir rescue therapy for chronic hepatitis B patients after suboptimal response to treatment with lamivudine plus adefovir dipivoxil].
    Ge Y; Li D; Fan Y; Yang H; Lyu W; Fan H; Zhou B; Liu X; Liu Z
    Zhonghua Nei Ke Za Zhi; 2014 Sep; 53(9):697-700. PubMed ID: 25511401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
    Menne S; Butler SD; George AL; Tochkov IA; Zhu Y; Xiong S; Gerin JL; Cote PJ; Tennant BC
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3617-32. PubMed ID: 18676881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
    Ryu HJ; Lee JM; Ahn SH; Kim DY; Lee MH; Han KH; Chon CY; Park JY
    J Med Virol; 2010 Nov; 82(11):1835-42. PubMed ID: 20872709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B.
    Park MS; Kim BK; Kim KS; Kim JK; Kim SU; Park JY; Kim DY; Baartarkhuu O; Han KH; Chon CY; Ahn SH
    Clin Mol Hepatol; 2013 Mar; 19(1):29-35. PubMed ID: 23593607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy.
    Lim L; Thompson A; Patterson S; George J; Strasser S; Lee A; Sievert W; Nicoll A; Desmond P; Roberts S; Marion K; Bowden S; Locarnini S; Angus P
    Liver Int; 2017 Jun; 37(6):827-835. PubMed ID: 27896895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.